Evidence map›Paper›PMID 29778254›Full record

ReviewInfectious disease clinics of North America2018

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings.

Anne C Moorman, Loralee B Rupp, Stuart C Gordon, Yuna Zhong, Jian Xing, Mei Lu, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Eyasu H Teshale and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Infectious disease clinics of North America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Hepatitis C Surveillance in the United States: Past, Present, and Future.Public health reports (Washington, D.C. : 1974) · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Observational
  8. Article
  9. Review
  10. Article
  11. Epidemiology of Hepatitis C.Clinical liver disease · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anne C MoormanDivision of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA. Electronic address: Amoorman@cdc.gov.
Loralee B RuppDivision of Gastroenterology and Hepatology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA.
Stuart C GordonDivision of Gastroenterology and Hepatology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA.
Yuna ZhongDivision of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA.
Jian XingDivision of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA.
Mei LuPublic Health Sciences, Henry Ford Health System, 1 Ford Place -3A, Detroit, MI 48202, USA.
Joseph A BoscarinoDepartment of Epidemiology and Health Services Research, Geisinger Clinic, 100 North Academy Avenue, Danville, PA 17822, USA.
Mark A SchmidtKaiser Permanente-Center for Health Research, Northwest, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227-1098, USA.
Yihe G DaidaKaiser Permanente-Center for Health Research, Hawaii, Kaiser Permanente Hawaii, 501 Alakawa Street, Suite 201, Honolulu, HI 9681, USA.
Eyasu H TeshaleDivision of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA.
Philip R SpradlingDivision of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA.
Scott D HolmbergDivision of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA.
CHeCS Investigators

Funding

Chronic Hepatitis Cohort Study–II (CHeCS–II)U18PS005154 · PS · HENRY FORD HEALTH SYSTEM · PI GORDON, STUART · 2016 to 2019
$1.4M
ACL HHS U18PS005154NCHHSTP CDC HHS U18 PS005154
6 · The paper itself

Abstract

Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.

Indexed as

Patient Reported Outcome MeasuresAdultAgedAntiviral AgentsCohort StudiesFemaleHepacivirusHepatitis C, ChronicHumansLiver CirrhosisMaleMiddle AgedObservational Studies as TopicRibavirinTime FactorsYoung AdultAntiviral AgentsRibavirinCirrhosisComorbiditiesDirect-acting antiviralHepatitis CMortalityReal-world cohortSustained viral response

Identifiers

PMID29778254
PMCPMC6211170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.